Tarsus Pharmaceuticals Quarterly Balance Sheet
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tarsus Pharmaceuticals financial position
As of Jun 30, 2026, Tarsus Pharmaceuticals reported total assets of $611.1 million, up 23.5% from a year earlier against total liabilities of $264.4 million. Shareholders' equity stood at $346.7 million, or 56.7% of assets. The company held $204.6 million in cash and equivalents against $72.8 million of debt, a net cash position of $131.8 million.
The current ratio (current assets divided by current liabilities) was 3.20, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.21.
Summary generated from market data by MetaCap's automated system. Methodology
Tarsus Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 204.59M | 102.19M | 183.64M | 112.72M | 96.65M | 175.79M | 94.82M | 176.21M | 181.09M | 193.71M | 224.95M | 226.67M |
| Short-Term Investments | 245.09M | 286.54M | 233.63M | 289.11M | 284.50M | 232.13M | 196.56M | 140.74M | 142.49M | 104.82M | 2.50M | 20.21M |
| Receivables | 96.03M | 100.34M | 85.06M | 72.62M | 58.33M | 62.43M | 46.76M | 29.16M | 29.53M | 29.89M | 16.62M | 5.36M |
| Inventory | 4.38M | 4.57M | 4.37M | 3.84M | 3.87M | 2.71M | 2.62M | 2.85M | 2.19M | 4.04M | 3.11M | 15.00K |
| Total Current Assets | 561.99M | 537.23M | 522.78M | 501.70M | 474.43M | 480.77M | 356.70M | 357.12M | 362.59M | 340.72M | 256.13M | 259.28M |
| Property, Plant & Equipment | 20.49M | 17.67M | 11.66M | 5.75M | 3.18M | 2.79M | 2.31M | 2.39M | 2.24M | 1.34M | 1.47M | 1.61M |
| Intangible Assets | 6.88M | 7.13M | 7.37M | 7.61M | 7.85M | 8.09M | 8.33M | 8.57M | 3.67M | 3.77M | 3.87M | 3.97M |
| Long-Term Investments | 6.68M | 3.87M | 3.87M | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M | 0 | 631.00K | 210.00K |
| Total Assets | 611.14M | 581.13M | 562.16M | 534.56M | 494.99M | 500.75M | 376.99M | 376.30M | 376.84M | 349.28M | 265.49M | 268.33M |
| Accounts Payable | 40.14M | 24.13M | 16.39M | 40.64M | 28.07M | 28.38M | 9.42M | 26.82M | 26.65M | 19.14M | 17.77M | 10.38M |
| Total Current Liabilities | 175.75M | 143.51M | 135.69M | 117.05M | 90.25M | 86.31M | 80.61M | 65.87M | 51.57M | 42.53M | 36.94M | 23.25M |
| Long-Term Debt | 72.76M | 72.60M | 72.44M | 72.28M | 72.13M | 71.98M | 71.84M | 71.71M | 71.58M | 29.93M | 29.82M | 29.71M |
| Total Liabilities | 264.41M | 232.18M | 218.73M | 199.48M | 162.38M | 158.29M | 152.46M | 138.82M | 124.60M | 74.07M | 68.50M | 54.67M |
| Shareholders' Equity | 346.73M | 348.95M | 343.43M | 335.08M | 332.61M | 342.46M | 224.53M | 237.48M | 252.25M | 275.21M | 196.99M | 213.66M |
| Retained Earnings | -452.15M | -433.60M | -426.63M | -418.25M | -405.67M | -385.33M | -360.21M | -337.10M | -313.68M | -280.39M | -244.66M | -202.75M |
| Total Debt | 72.76M | 72.60M | 72.44M | 72.28M | 72.13M | 71.98M | 71.84M | 71.71M | 71.58M | 29.93M | 29.82M | 29.71M |
| Net Cash (Debt) | 376.93M | 316.13M | 344.83M | 329.56M | 309.01M | 335.93M | 219.53M | 245.24M | 252.00M | 268.59M | 197.62M | 217.18M |
| Shares Outstanding | 43.27M | 43.02M | 42.55M | 42.45M | 42.21M | 42.00M | 38.35M | 38.20M | 38.03M | 37.75M | 34.21M | 33.10M |
This table shows 12 quarterly periods of Tarsus Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TARS's reporting calendar. What is a balance sheet?